Pilar Tavares Veras Florentino

Pilar Tavares Veras Florentino

Auto-generated profile, based on publicly available information

Pilar Tavares Veras Florentino

Centro de Integração de Dados e Conhecimento em Saúde (CIDACS), Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, R. Mundo, 121 - sala 315 - Trobogy, Salvador, 41745-715, Brazil, 55 7131762357

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2022 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
PFPilar T V Florentino
Pilar T V Florentino
TMTristan Millington
Tristan Millington
TCThiago Cerqueira-Silva
Thiago Cerqueira-Silva
CRChris Robertson
Chris Robertson
VOVinicius de Araújo Oliveira
Vinicius de Araújo Oliveira
EPEnny S Paixão
Enny S Paixão
Little is known about vaccine effectiveness over time among adolescents, especially against the SARS-CoV-2 omicron (B.1.1.529) variant. This study assessed the associations between time since two-dose vaccination with BNT162b2 and the occurrence of symptomatic SARS-CoV-2 infection and severe COVID-19 among adolescents in Brazil and Scotland. We did test-negative, case-control studies in adolescents aged 12–17 years with COVID-19-related symptoms in Brazil and Scotland. We linked records of SARS-CoV-2 RT-PCR and antigen tests to national vaccination and clinical records. We excluded tests from individuals who did not have symptoms, were vaccinated before the start of the national vaccination programme, received vaccines other than BNT162b2 or a SARS-CoV-2 booster dose of any kind, or had an interval between their first and second dose of fewer than 21 days. Additionally, we excluded negative SARS-CoV-2 tests recorded within 14 days of a previous negative test, negative tests recorded within 7 days after a positive test, any test done within 90 days after a positive test, and tests with missing sex and location information. Cases (SARS-CoV-2 test-positive adolescents) and controls (test-negative adolescents) were drawn from a sample of individuals in whom tests were collected within 10 days of symptom onset. We estimated the adjusted odds ratio and vaccine effectiveness against symptomatic COVID-19 for both countries and against severe COVID-19 (hospitalisation or death) for Brazil across fortnightly periods. We analysed 503 776 tests from 2 948 538 adolescents in Brazil between Sept 2, 2021, and April 19, 2022, and 127 168 tests from 404 673 adolescents in Scotland between Aug 6, 2021, and April 19, 2022. Vaccine effectiveness peaked at 14–27 days after the second dose in both countries during both waves, and was significantly lower against symptomatic infection during the omicron-dominant period in Brazil (64·7% [95% CI 63·0–66·3]) and in Scotland (82·6% [80·6–84·5]), than it was in the delta-dominant period (80·7% [95% CI 77·8–83·3] in Brazil and 92·8% [85·7–96·4] in Scotland). Vaccine efficacy started to decline from 27 days after the second dose for both countries, reducing to 5·9% (95% CI 2·2–9·4) in Brazil and 50·6% (42·7–57·4) in Scotland at 98 days or more during the omicron-dominant period. In Brazil, protection against severe disease remained above 80% from 28 days after the second dose and was 82·7% (95% CI 68·8–90·4) at 98 days or more after receiving the second dose. We found waning vaccine protection of BNT162b2 against symptomatic COVID-19 infection among adolescents in Brazil and Scotland from 27 days after the second dose. However, protection against severe COVID-19 outcomes remained high at 98 days or more after the second dose in the omicron-dominant period. Booster doses for adolescents need to be considered. UK Research and Innovation (Medical Research Council), Scottish Government, Health Data Research UK BREATHE Hub, Fiocruz, Fazer o Bem Faz Bem programme, Brazilian National Research Council, and Wellcome Trust. For the Portuguese translation of the abstract see Supplementary Materials section.

13 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
PFPilar T. V. Florentino
Pilar T. V. Florentino
FAFlávia J. O. Alves
Flávia J. O. Alves
TCThiago Cerqueira-Silva Cerqueira-Silva
Thiago Cerqueira-Silva Cerqueira-Silva
VOVinicius de Araújo Oliveira
Vinicius de Araújo Oliveira
JJJuracy B. S. Júnior
Juracy B. S. Júnior
EPEnny S. Paixão
Enny S. Paixão
Although severe COVID-19 in children is rare, they may develop multisystem inflammatory syndrome, long-COVID and downstream effects of COVID-19, including social isolation and disruption of education. Data on the effectiveness of the CoronaVac vaccine is scarce during the Omicron period. In Brazil, children between 6 to 11 years are eligible to receive the CoronaVac vaccine. We conducted a test-negative design to estimate vaccine effectiveness using 197,958 tests from January 21, 2022, to April 15, 2022, during the Omicron dominant period in Brazil among children aged 6 to 11 years. The estimated vaccine effectiveness for symptomatic infection was 39.8% (95% CI 33.7–45.4) at ≥14 days post-second dose. For hospital admission vaccine effectiveness was 59.2% (95% CI 11.3–84.5) at ≥14 days. Two doses of CoronaVac in children during the Omicron period showed low levels of protection against symptomatic infection, and modest levels against severe illness.

7 April 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
PFPilar T. V. Florentino
Pilar T. V. Florentino
DMDavi Mendes
Davi Mendes
FVFrancisca Nathalia de Luna Vitorino
Francisca Nathalia de Luna Vitorino
DMDavi J. Martins
Davi J. Martins
JCJulia P. C. Cunha
Julia P. C. Cunha
CMCarlos FM Menck
Carlos FM Menck
Trypanosoma cruzi is the etiologic agent of Chagas’ disease. Infected cells with T. cruzi activate several responses that promote unbalance of reactive oxygen species (ROS) that may cause DNA damage that activate cellular responses including DNA repair processes. In this work, HeLa cells and AC16 human cardiomyocyte cell line were infected with T. cruzi to investigate host cell responses at genome level during parasites intracellular life cycle. In fact, alkaline sensitive sites and oxidized DNA bases were detected in the host cell genetic material particularly in early stages of infection. These DNA lesions were accompanied by phosphorylation of the histone H2Ax, inducing γH2Ax, a marker of genotoxic stress. Moreover, Poly [ADP-ribose] polymerase-1 (PARP1) and 8-oxoguanine glycosylase (OGG1) are recruited to host cell nuclei, indicating activation of the DNA repair process. In infected cells, chromatin-associated proteins are carbonylated, as a possible consequence of oxidative stress and the nuclear factor erythroid 2–related factor 2 (NRF2) is induced early after infection, suggesting that the host cell antioxidant defenses are activated. However, at late stages of infection, NRF2 is downregulated. Interestingly, host cells treated with glutathione precursor, N-acetyl cysteine, NRF2 activator (Sulforaphane), and also Benznidonazol (BNZ) reduce parasite burst significantly, and DNA damage. These data indicate that the balance of oxidative stress and DNA damage induction in host cells may play a role during the process of infection itself, and interference in these processes may hamper T. cruzi infection, revealing potential target pathways for the therapy support.

10 September 2023 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
PFPilar Tavares Veras Florentino
Pilar Tavares Veras Florentino
TCThiago Cerqueira-Silva
Thiago Cerqueira-Silva
LCLuciana Freire De Carvalho
Luciana Freire De Carvalho
FAFlávia Jôse Oliveira Alves
Flávia Jôse Oliveira Alves
VOVinicius De Araújo Oliveira
Vinicius De Araújo Oliveira
EPEnny S. Paixão
Enny S. Paixão
Background: COVID-19 vaccines have been shown to protect pregnant individuals against mild and severe COVID-19 outcomes. However, limited safety data are available for inactivated (CoronaVac) and mRNA (BNT162b2) vaccines during pregnancy regarding their effect on birth outcomes and neonatal mortality, especially in low- and middle-income countries. Methods: We conducted a retrospective population-based cohort study in Rio de Janeiro, Brazil, with 17 513 singleton live births conceived between 15 May 2021 and 23 October 2021. The primary exposure was maternal vaccination with CoronaVac or mRNA BNT162b2 vaccines and sub-analyses were performed by the gestational trimester of the first dose and the number of doses given during pregnancy. The outcomes were pre-term birth (PTB), small for gestational age (SGA), low birthweight (LBW), low Apgar 5 and neonatal death. We used the Cox model to estimate the hazard ratio (HR) with a 95% CI and applied the inverse probability of treatment weights to generate adjusted HRs. Results: We found no significant increase in the risk of PTB (HR: 0.98; 95% CI 0.88, 1.10), SGA (HR: 1.09; 95% CI 0.96, 1.27), LBW (HR: 1.00; 95% CI 0.88, 1.14), low Apgar 5 (HR: 0.81; 95% CI 0.55, 1.22) or neonatal death (HR: 0.88; 95% CI 0.56, 1.48) in women vaccinated with CoronaVac or BNT162b2 vaccines. These findings were consistent across sub-analyses stratified by the gestational trimester of the first dose and the number of doses given during pregnancy. We found mild yet consistent protection against PTB in women who received different vaccine platforms during the third trimester of pregnancy (any vaccines, HR: 0.78; 95% CI 0.63, 0.98; BNT162b2, HR: 0.75; 95% CI 0.59, 0.99). Conclusions: This study provides evidence that COVID-19 vaccination in all trimesters of pregnancy, irrespective of the vaccine type, is safe and does not increase the risk of adverse birth outcomes or neonatal deaths.

1 January 2024 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
TCThiago Cerqueira-Silva Cerqueira-Silva
Thiago Cerqueira-Silva Cerqueira-Silva
JOJuliane Oliveira
Juliane Oliveira
VOVinicius de Araújo Oliveira
Vinicius de Araújo Oliveira
PFPilar Tavares Veras Florentino
Pilar Tavares Veras Florentino
ASAlberto Sironi
Alberto Sironi
IMIzabel Marcilio
Izabel Marcilio
Syndromic surveillance using primary health care (PHC) data is a valuable tool for early outbreak detection, as demonstrated by the potential to identify COVID-19 outbreaks. However, the potential of such an early warning system in the post-COVID-19 era remains largely unexplored. We analyzed PHC encounter counter of respiratory complaints registered in the database of the Brazilian Unified National Health System from October 2022 to July 2023. We applied EARS (variations C1/C2/C3) and EVI to estimate the weekly thresholds. An alarm was determined when the number of encounters exceeded the week-specific threshold. We used data on hospitalization due to respiratory disease to classify as anomalies the weeks in which the number of cases surpassed predetermined thresholds. We compared EARS and EVI efficacy in anticipating anomalies. A total of 119 anomalies were identified across 116 immediate regions during the study period. The EARS-C2 presented the highest early alarm rate, with 81/119 (68%) early alarms, and C1 the lowest, with 71 (60%) early alarms. The lowest true positivity was the EARS-C1 118/1,354 (8.7%) and the highest was EARS-C3 99/856 (11.6%). Routinely collected PHC data can be successfully used to detect respiratory disease outbreaks in Brazil. Syndromic surveillance enhances timeliness in surveillance strategies, albeit with lower specificity. A combined approach with other strategies is essential to strengthen accuracy, offering a proactive and effective public health response against future outbreaks.

1 January 2020 in Genetics and Molecular Biology
Verified
Journal Article
Open access
PDF file
BRBruno M. Repolês
Bruno M. Repolês
CMCarlos Renato Machado
Carlos Renato Machado
PFPilar T.V. Florentino
Pilar T.V. Florentino
Pathological processes such as bacterial, viral and parasitic infections can generate a plethora of responses such as, but not restricted to, oxidative stress that can be harmful to the host and the pathogen. This stress occurs when there is an imbalance between reactive oxygen species produced and antioxidant factors produced in response to the infection. This imbalance can lead to DNA lesions in both infected cells as well as in the pathogen. The effects of the host response on the parasite lead to several kinds of DNA damage, causing alterations in the parasite's metabolism; the reaction and sensitivity of the parasite to these responses are related to the DNA metabolism and life cycle of each parasite. The present review will discuss the survival strategies developed by host cells and Trypanosoma cruzi, focusing on the DNA repair mechanisms of these organisms throughout infection including the relationship between DNA damage, stress response features, and the unique characteristics of these diseases.